Stanford set for drug trial boost
Sunday 28 September 1997
An independent safety board is meeting this weekend to tabulate the results of a "phase III," or final-stage clinical trial on several hundred patients in South Africa, where the infectious disease is prevalent, according to Robin Gilbert, analyst with Panmure Gordon.
The results are expected to reflect those of earlier trials in Vietnam, which showed the drug, SRL172, was more effective against the disease when used with common antibiotics made by Novartis, Hoechst and others, than on its own.
"If the Vietnamese trial results are reproduced over here, they could have themselves a blockbuster," said Erling Refsum, analyst at Yamaichi International (Europe). "We already know the drug works. This trial is more of a regulatory hoop they have to go through to get approval."
Stanford Rook shares have risen 19 per cent in the last five days, from a 52-week low of 445p to 531.5p in anticipation of the results.
The company, which is also developing the same "immunotherapy" drug as a treatment for various cancers and HIV, has said it plans to file for approval for the drug as a tuberculosis treatment in 1998.
Tuberculosis kills about 3 million people each year, mostly in developing regions such as Africa and Asia.
- 3 The enemy within: People who hear voices in their heads are being encouraged to talk back
- 4 British grandmother Lindsay Sandiford faces execution by firing squad in Indonesia
'We would evict Queen from Buckingham Palace and allocate her council house,' say Greens
French court convicts three over homophobic tweets, in case hailed as a 'significant victory' by LGBT rights campaigners
Greece elections: Syriza and EU on collision course after election win for left-wing party
British Muslim school children suffering a backlash of abuse following Paris attacks
Islamic history is full of free thinkers - but recent attempts to suppress critical thought are verging on the absurd
30,000 reasons why the rhetoric on immigrants claiming benefits can stop now
iJobs Money & Business
£30000 - £32000 per annum + benefits : Ashdown Group: A highly successful, int...
£18000 - £20000 per annum: Recruitment Genius: This rapidly expanding business...
£25 - 28k + Bonus: Guru Careers: An In-house / Internal Recruiter is needed to...
Negotiable: Recruitment Genius: A Tax Assistant is required to join a leading ...